01Planned
Formulation & filling
Filling activity including lyophilisation for the presentation families listed below.
Planned aseptic fillingManufacturing · Boten
The Boten manufacturing project.
Two planned production modules, five formulation-and-filling presentation families, and a staged implementation sequence documented in the June 2026 project brief.
Source status
Boten Biopharmaceutical Manufacturing Project15 June 2026 · planning documentThis source describes intended project architecture and sequence. It is not evidence that the facility is commissioned, licensed or operating at the described scope.
Current project stageIn progress
Construction and fit-out.
Construction is in its final stage; completion is an indicative target.
Target Q4 2026 · indicative · Status reviewed
- Project stage
- Construction and fit-outIn progress
- Next project step
- Equipment installation and qualificationTarget Q1 2027 · indicative
- Status reviewed
- Project update
- Operating evidence
- None presented as issuedNo commissioned line, licence or GMP certificate
01 · Project status
Development-stage, not operating-stage.
The project brief describes a pharmaceutical manufacturing facility planned for Boten Economic Zone, Lao PDR. For this website, that record is treated as a development plan.
No manufacturing licence, GMP certificate, product registration or commissioned-line evidence is represented here as issued.
| Evidence level | Record | Boundary |
|---|---|---|
| Current project record | Construction and fit-out · in progress | Status reviewed . |
| Planned scope | Formulation and filling; protein raw-material production and purification | A plan does not establish installed equipment or a validated process. |
| Operating evidence | None presented as issued | No commissioned-line, manufacturing-licence or GMP-certificate evidence. |
Interpretation rule
Planned equipment, presentation families, implementation timing and production architecture must not be read as current installed capability or an approved scope.
02 · Planned modules
Two-module production architecture.
Each module carries its own evidence requirements.
02Planned
Protein raw-material production & purification
Protein raw-material production and purification.
Planned drug-substance scope| Module | Source-plan scope | Website status |
|---|---|---|
| 01 · Formulation & filling | Filling activity including lyophilisation for the presentation families listed below. | Planned development scope. |
| 02 · Protein raw-material production & purification | Protein raw-material production and purification. | Planned development scope. |
03 · Formulation & filling
Five presentation families in the source plan.
| Presentation | Illustration | Planning description | Status |
|---|---|---|---|
| Lyophilised vial |  | Vial presentation with lyophilisation identified in the source plan. | Planned |
| Dual-chamber cartridge |  | Dual-chamber cartridge presentation identified in the source plan. | Planned |
| Single-chamber lyophilised cartridge |  | Single-chamber cartridge presentation with lyophilisation identified in the source plan. | Planned |
| 10 mL oil-based vial injection |  | Oil-based injection in a 10 mL vial identified in the source plan. | Planned |
| 1 mL ampoule injection |  | Injection in a 1 mL ampoule identified in the source plan. | Planned |
Images are illustrative unbranded object details. It does not depict Luang Pharma's project, products or installed equipment.
The source-plan list does not establish molecule compatibility, validated process parameters, installed line state or marketing authorisation for a particular product.
04 · Implementation sequence
A four-phase planning sequence.
- Phase 1
Workshop design and construction.
Layout confirmation and cleanroom construction milestones by scope.
- Phase 2
Equipment procurement, transportation and installation.
Major equipment delivery and mechanical installation.
- Phase 3
Utilities connection, equipment commissioning, HVAC/purification validation, GMP documentation baseline, and raw-material/packaging procurement.
Utilities commissioning, HVAC verification and GMP document baseline.
- Phase 4
Personnel training, trial production, process validation, product testing, and manufacturing-licence application.
Trial batches, validation records, testing reports and licence-application package.
Planning sequence, not promised schedule
Licence application is not licence grant. Trial work, validation, testing and routine manufacturing each require the permissions and controls appropriate to the activity.
05 · Indicative project roadmap
Each milestone remains visible.
Quarters are indicative project targets, never service dates.
- 01Completed
Facility design
Facility design is recorded as complete. No completion date is supplied.
- 02In progressTarget Q4 2026 · indicative
Construction and fit-out
Construction is in its final stage; completion is an indicative target.
- 03PlannedTarget Q1 2027 · indicative
Equipment installation and qualification
Installed systems would require documented qualification.
- 04PlannedTarget Q2 2027 · indicative
Process and system validation
Process and system evidence would need to be established.
- 05PlannedTarget Q3 2027 · indicative
Manufacturing licence application
Submitting an application does not establish permission to manufacture.
- 06PlannedTarget Q4 2027 · indicative
Regulatory inspection
Inspection is a separate stage from any resulting authorisation.
- 07PlannedTarget Q1 2028 · indicative
First commercial batch
Dependent on applicable permissions and demonstrated readiness.
Project roadmap reviewed . These are indicative project targets, subject to progress and applicable permissions. They are not service launch dates or commitments to supply. A milestone is marked completed only when the company confirms it.
06 · Evidence dependencies
Construction is only one layer of manufacturing readiness.
01
Installed systems
Equipment, utilities and controlled environments must match the intended operation.
02
Qualification & validation
Evidence must show systems and processes perform as intended within their defined scope.
03
Controlled quality system
Procedures, records, training, deviations, change control and release responsibilities must be established.
04
Applicable permissions
Facility and product permissions remain jurisdiction- and scope-specific.
Read the quality approach and regulatory approach for the distinction between these evidence layers.
07 · Portfolio relationship
The public portfolio is broader than this first project scope.
Oral solid dosage forms, other non-initial presentations, devices and diagnostics in the public portfolio are development records. They must not be interpreted as existing Boten production lines. For any proposed product, the actual manufacturing route, technical responsibilities, product status and destination requirements need separate confirmation.
Planned capabilities
The planned capabilities catalogue lists a wider set of future manufacturing and service interests, each marked Planned. Catalogue expansion requires product-, process-, site- and jurisdiction-specific confirmation. Explore the catalogue
08 · Project evidence
Use the source and the photographs for what they establish.
The project brief establishes the documented planning position as of its date. Owner-supplied imagery records visible project activity. Neither source, by itself, proves regulatory approval, operating readiness or present capacity.
- Planning document
- Boten Biopharmaceutical Manufacturing Project · 15 June 2026Initial scope and project sequence.
- Stage update
- Reviewed Current construction stage and indicative future milestones.
- Project photography
- Owner-authorised meeting image; no exact event date asserted.
- Construction footage
- Owner-supplied earlier-stage footage; filename timestamp is not treated as a verified event date.
Professional enquiries
Discuss the Boten manufacturing project.
State your organisation, technical subject and intended product or market context. Planned scope and current evidence will be distinguished in the response.